Bronchodilator Drugs - Botswana | Statista Market Forecast

The Bronchodilator Drugs market in Botswana is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$2.75m Pula by the year 2024.
Furthermore, it is anticipated that there will be an annual growth rate of 4.13% between 2024 and 2029, resulting in a market volume of US$3.37m Pula by the end of 2029.
When comparing the revenue generated globally, it is noteworthy that United States is expected to lead the market with a projected revenue of US$17.34bn in 2024.
Botswana's market for bronchodilator drugs is experiencing a surge in demand due to the high prevalence of respiratory conditions in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used in Botswana to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been steadily growing in recent years due to various factors.

Customer preferences: Patients in Botswana prefer bronchodilator drugs that are affordable, effective, and have minimal side effects. They also prefer drugs that are easy to administer and can be used for both short-term and long-term treatment.

Trends in the market: The market for bronchodilator drugs in Botswana has been growing due to the increasing prevalence of respiratory diseases in the country. According to the World Health Organization (WHO), the prevalence of asthma in Botswana is estimated to be around 15% among children and 10% among adults. Additionally, the rising awareness about the benefits of early diagnosis and treatment of respiratory diseases has also contributed to the growth of the market. The market is dominated by short-acting bronchodilators such as salbutamol and terbutaline, which are used for quick relief of asthma symptoms. However, long-acting bronchodilators such as formoterol and salmeterol are also gaining popularity due to their effectiveness in providing long-term relief from symptoms.

Local special circumstances: Botswana has a high burden of HIV/AIDS, which has been linked to an increased risk of respiratory infections and diseases. This has led to a higher demand for bronchodilator drugs in the country. Additionally, Botswana is a landlocked country with a small population, which means that the market for bronchodilator drugs is relatively small compared to other countries.

Underlying macroeconomic factors: The healthcare sector in Botswana has been growing in recent years due to increased government spending on healthcare infrastructure and services. This has led to improved access to healthcare services, including respiratory care. Additionally, the country's stable political environment and favorable business climate have attracted foreign investment, which has contributed to the growth of the healthcare sector. However, the market for bronchodilator drugs in Botswana is still largely dependent on imports, which makes it vulnerable to fluctuations in exchange rates and international trade policies.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.